| Title: |
Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort |
| Authors: |
Di Donato, S.; Pauling, J.D.; Ramjug, S.; Allanore, Y.; Jude, E.B.; Truchetet, M.-E.; Airò, P.; Ananyeva, L.P.; Balanescu, A.; Boleto, G.; Cantatore, F.P.; Carreira, P.E.; de Souza Müller, C.; Kuwana, M.; Moroncini, G.; Di Battista, M.; Mouthon, L.; Vonk, M.C.; Zanatta, E.; Matucci-Cerinic, M.; Del Galdo, F.; Hughes, M.; Guiducci, S.; Randone, S.B.; Walker, U.; Iannone, F.; Distler, O.; Becvar, R.; Bielecka, O.K.; Cutolo, M.; Liakouli, V.; Siegert, E.; Rednic, S.; Avouac, J.; Montecucco, C.; Czirják, L.; Iudici, M.; Perdan-Pirkmajer, K.; Coleiro, B.; Bancel, D.F.; Andréasson, K.; Radic, M.; Balbir-Gurman, A.; Hunzelmann, N.; Idolazzi, L.; Christopher; Denton; Henes, J.; Ortiz-Santamaria, V.; Pflugfelder, J.; Krasowska, D.; Foeldvari, I.; da Silva, J.A.P.; Stamenkovic, B.; De Santis, M.; Ananieva, L.P.; Klemm, P.; Müller-Ladner, U.; Søndergaard, K.; Negrini, S.; Szücs, G.; Hoffmann-Vold, A.-M.; Launay, D.; Riccieri, V.; Gheorghiu, A.M.; Bergmann, C.; Ingegnoli, F.; Smith, V.; Mogensen, M.; Pozzi, M.R.; Lauffer, F.; Vanthuyne, M.; Alegre-Sancho, J.J.; Aringer, M.; De Langhe, E.; Ani, B.; Yavuz, S.; Agachi, S.; Cauli, A.; Solanki, K.; Loyo, E.; Rosato, E.; Zhini, F.Y.; Foti, R.; Maurer, B.; Olesinska, M.; Martín, J.J.G.; Chatelus, E.; Litinsky, I.; Saketkoo, L.A.; Kerzberg, E.; Bianchi, B.V.; Castellví, I.; Limonta, M.; Couto, M.; Ribi, C.; Marcoccia, A.; Martin, T.; Chung, L.S.; Schmeiser, T.; Majewski, D.; Wojteczek, A.; Bernardino, V.; Riemekasten, G.; Levy, Y.; Rezus, E.; Talotta, R.; Bongiovanni, S.; Brzosko, M.; Poormoghim, H.; Kötter, I.; Cuomo, G.; Epis, O.M.; Sfikakis, P.; Furst, D.; Ramazan, A.-M.; de Vries-Bouwstra, J.; Lescoat, A.; Spierings, J.; Atzeni, F.; Mekinian, A.; Martin, M.; Tanaka, Y.; Simeón-Aznar, C.-P.; Pârvu, M.; Del Papa, N.; Kastrati, K.; Shimol, J.B.; Selvi, E.; Soukup, T.; Kawaguchi, Y.; Conde, A.N.; Geroldinger-Simic, M.; Rodríguez-Pintó, I.; Sampaio-Barros, P.D.; Gerth, U.; Dzhus, M.; Karadag, D.T.; Batalov, A.; Ginosyan, K.; Mukuchyan, V.; Vardanyan, V.; Haroyan, A.; Harty, L.; Geneva-Popova, M.; Naffaa, M.; Maglio, C.; Masato, O.; Futoshi, I. |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2025 |
| Collection: |
White Rose Research Online (Universities of Leeds, Sheffield & York) |
| Description: |
Objectives Systemic sclerosis (SSc) is characterized by widespread vascular damage resulting in digital and systemic vasculopathic sequelae. Although there are effective treatments available, vascular disease remains a significant cause of morbidity and mortality in SSc. Our aim was to describe patterns of vascular medication use in SSc, including examination for potential changes over time. Methods A cross-sectional study of SSc patients enrolled in the EUSTAR database meeting 2013 ACR/EULAR SSc criteria. Patients were divided into two time periods: 2012–2017 and 2018–2022. We analysed the prescription patterns of endothelin receptor antagonists (ERA), phosphodiesterase type-5 inhibitors (PDE5i), calcium channel blockers (CCB), intravenous iloprost, and antiplatelet therapies. Logistic regression was used to evaluate temporal trends and interaction effects. Results A total of 8079 patients were included. Significant increases over time were observed in the use of ERA (7% to 12%, P < 0.001), PDE5i (5.4% to 7.2%, P = 0.064), CCB (20% to 32%, P < 0.001) and anti-platelet therapies (15% to 20%, P < 0.001). There was a notable decrease in iloprost use (3.1% to 0.3%, P < 0.001). The prevalence of active digital ulcers (DU) decreased (16% to 13%, P = 0.040), while a history of DU (24% to 30%, P < 0.001) increased. Year-by-year and non-linear increases were noted for ERA and CCB whereas non-linear increase was observed for PDE5i. Year-by-year and non-linear decrease was observed for Iloprost prescription. Conclusion A significant change has occurred over time in vascular medication use in SSc patients, with increased utilization of ERA, PDE5i, CCB and anti-platelet therapies suggesting the adoption of more proactive and/or preventive treatment strategies. |
| Document Type: |
article in journal/newspaper |
| File Description: |
text |
| Language: |
English |
| ISSN: |
1462-0324 |
| Relation: |
https://eprints.whiterose.ac.uk/id/eprint/229582/3/20250513%20Temporal%20trends%20in%20vascular_medications_trend_final_manuscript_approved.pdf; Di Donato, S. orcid.org/0000-0003-1256-0761 , Pauling, J.D., Ramjug, S. et al. (149 more authors) (2025) Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort. Rheumatology. keaf290. ISSN: 1462-0324 |
| Availability: |
https://eprints.whiterose.ac.uk/id/eprint/229582/; https://eprints.whiterose.ac.uk/id/eprint/229582/3/20250513%20Temporal%20trends%20in%20vascular_medications_trend_final_manuscript_approved.pdf |
| Rights: |
cc_by_4 |
| Accession Number: |
edsbas.8522D567 |
| Database: |
BASE |